Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

5/20/24 2:33:01 PM ET

$KRRO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KRRO alert in real time by email

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model
KRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13

Get the next $KRRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KRRO

Date	Price Target	Rating	Analyst
10/21/2024	$153.00	Strong Buy	Raymond James
8/14/2024	$180.00	Outperform	William Blair
3/28/2024	$100.00 → $115.00	Buy	H.C. Wainwright
2/27/2024	$120.00	Outperform	BMO Capital Markets
12/4/2023	$100.00	Buy	H.C. Wainwright
11/29/2023	$70.00	Outperform	RBC Capital Mkts
11/10/2023	$180.00	Overweight	Piper Sandler

More analyst ratings

$KRRO
Press Releases

Fastest customizable press release news feed in the world

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced a submission to t
11/4/24 7:25:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company's first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single
9/30/24 8:00:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development
9/16/24 8:00:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
8/28/24 8:00:00 AM ET
$KRRO
$MRKR
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company
5/14/24 4:01:00 PM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
Biotech veteran brings more than two decades of life science experience to Korro's Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform, today announced the appointment of Rachel Meyers, PhD, to the Company's Board of Directors. "Rachel is one of the pioneers in advancing LNP and conjugate-based oligonucleotide therapies to the clinic and generating regulatory approvals," said Ram Aiyar, PhD, Chief Executive Officer of Korro. "With over two decades of research, development and
11/28/23 8:00:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care

Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

Chat with this insight

Recent Analyst Ratings for $KRRO

$KRRO Market Insights

Live Market Insights

Korro Bio Joins Russell 2000, Russell 3000 And Russell Microcap Indexes

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target

Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

$KRRO SEC Filings

SEC Form 424B3 filed by Korro Bio Inc.

SEC Form 424B3 filed by Korro Bio Inc.

Korro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$KRRO Press Releases

Fastest customizable press release news feed in the world

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

$KRRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Agarwal Vineet sold $799,527 worth of shares (10,216 units at $78.26) and exercised 10,216 shares at a strike of $11.99 (SEC Form 4)

SEC Form 4 filed by General Counsel Cerio Jeffrey

SEC Form 3 filed by new insider Cerio Jeffrey

$KRRO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

$KRRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

SEC Form SC 13G filed by Korro Bio Inc.

SEC Form SC 13D/A filed by Korro Bio Inc. (Amendment)

$KRRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James initiated coverage on Korro Bio with a new price target

William Blair initiated coverage on Korro Bio with a new price target

H.C. Wainwright reiterated coverage on Korro Bio with a new price target

$KRRO Leadership Updates

Live Leadership Updates

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Recent Analyst Ratings for
$KRRO

$KRRO
Market Insights

$KRRO
SEC Filings

$KRRO
Press Releases

$KRRO
Insider Trading

$KRRO
Insider Purchases

$KRRO
Large Ownership Changes

$KRRO
Analyst Ratings

$KRRO
Leadership Updates